Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chiara D'Antonio is active.

Publication


Featured researches published by Chiara D'Antonio.


Journal of Gastrointestinal and Liver Diseases | 2014

Circulating tumor cells count predicts survival in colorectal cancer patients

Adriana Romiti; Salvatore Raffa; Roberta Di Rocco; Michela Roberto; Annalisa Milano; Angelo Zullo; Laura Leone; Danilo Ranieri; Francesca Mazzetta; Emanuela Medda; Ida Sarcina; Viola Barucca; Chiara D'Antonio; Valeria Durante; Mario Ferri; Maria Rosaria Torrisi; Paolo Marchetti

Background & Aims: Respiratory complications represent an important adverse event of endoscopic procedures. We screened for respiratory complications aer endoscopic procedures using a questionnaire and followed-up patients suggestive of respiratory infection. Method: In this prospective observational, multicenter study performed in Outpatient practices of gastroenterology we investigated 15,690 patients by questionnaires administered 24 hours aer the endoscopic procedure. Results: 832 of the 15,690 patients stated at least one respiratory symptom aer the endoscopic procedure: 829 patients reported coughing (5.28%), 23 fever (0.15%) and 116 shortness of breath (SOB, 0.74%); 130 of the 832 patients showed at least two concomitant respiratory symptoms (107 coughing + SOB, 17 coughing + fever, 6 coughing + coexisting fever + SOB) and 126 patients were followed-up to assess their respiratory complaints. Twenty-nine patients (follow-up: 22.31%, whole sample: 0.18%) reported signs of clinically evident respiratory infection and 15 patients (follow-up: 11.54%; whole sample: 0.1%) received therefore antibiotic treatment. Coughing or vomiting during the endoscopic procedure resulted in a 156.12-fold increased risk of respiratory complications (95% CI: 67.44 - 361.40) and 520.87-fold increased risk of requiring antibiotic treatment (95% CI: 178.01 - 1524.05). All patients of the follow-up sample who coughed or vomited during endoscopy developed clinically evident signs of respiratory infection and required antibiotic treatment while this occurred in a signicantly lower proportion of patients without these symptoms (17.1% and 5.1%, respectively). Conclusions: We demonstrated that respiratory complications following endoscopic sedation are of comparably high incidence and we identied major predictors of aspiration pneumonia which could inuence future surveillance strategies aer endoscopic procedures.


Anti-Cancer Drugs | 2016

A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer

Michela Roberto; Adriana Romiti; Concetta Elisa Onesti; Chiara D'Antonio; Annalisa Milano; Rosa Falcone; Viola Barucca; Lucia Palombi; Riccardo Righini; Paolo Marchetti

In recent years, metronomic chemotherapy, consisting of continuous administration of low doses of cytotoxic agents, has being used as rescue therapy for different tumours. The aim of this study was to retrospectively assess the efficacy and safety of low-dose metronomic, oral capecitabine in pretreated or frail patients with recurrent upper gastrointestinal tract cancer. Patients with pretreated upper gastrointestinal tract cancer or who were not candidates for standard chemotherapy because of toxicity concerns received capecitabine at 1500 mg per day continuously until disease progression or occurrence of toxicity. Forty-seven patients (25 oesophagogastric cancer, 22 pancreatobiliary cancer; 25 men, 22 women; median age 69 years, range 42–90) were included in the study. Forty-five percent of the patients had received at least two previous lines of treatment and the median number of previous treatments was 1 (range 0–5). Twelve (31.6%) patients achieved clinical benefit (one partial response, 11 stable disease), whereas nine (23.7%) patients were progression free for at least 6 months. In an exploratory analysis, there was a significant relationship between performance status and clinical benefit (hazard ratio=8.25; P=0.01). The median overall survival was 5 months. A good performance status was associated with a longer survival (hazard ratio=0.26; P<0.01). No severe toxicity or treatment-related death was reported. Metronomic capecitabine showed good safety and moderate activity in frail or pretreated patients with advanced, upper gastrointestinal tract cancer.


Journal of Thoracic Oncology | 2012

Complete Regression of a Non-small Cell Lung Cancer Choroidal Metastasis with Intravitreal Bevacizumab

Chiara D'Antonio; Antonella Viterbo; Adriana Romiti; Maurizio Maurizi Enrici; Salvatore Lauro; Paolo Marchetti

CASE REPORT A 34-year-old woman presented in July 2009 at our institution with choroidal metastasis as first manifestation of a non-small cell lung cancer. Symptoms of disease were a progressive vision loss in the left eye and diplopia. The ophthalmoscopy showed a big choroidal mass with secondary subretinal fluid in the left eye; fluorescein angiograms, the optical coherence tomography (Figure 1A), and an ultrasound retinal examination (Figure 2A) confirmed the alteration of choroidal. A total body computed tomography scan revealed a voluminous mass in the upper right lung, small multiple bilateral pulmonary nodules, and mediastinal lymphadenopathy. Pathologic diagnosis of invasive papillary adenocarcinoma was obtained from a transthoracic needle biopsy of the upper right lung.


International Journal of Cardiology | 2013

Arterial thrombotic events and acute coronary syndromes with cancer drugs: Are growth factors the missed link? What both cardiologist and oncologist should know about novel angiogenesis inhibitors

Elena Conti; Adriana Romiti; Maria Beatrice Musumeci; Jasmine Passerini; Luigi Zezza; Vittoria Mastromarino; Chiara D'Antonio; Paolo Marchetti; Francesco Paneni; Camillo Autore; Massimo Volpe


Medical Oncology | 2015

Continuous, low-dose capecitabine for patients with recurrent colorectal cancer

Adriana Romiti; Concetta Elisa Onesti; Michela Roberto; Viola Barucca; Silverio Tomao; Chiara D'Antonio; Valeria Durante; Annalisa Milano; Rosa Falcone; Roberta Di Rocco; Riccardo Righini; Paolo Marchetti


Anticancer Research | 2014

Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know

Chiara D'Antonio; Annalisa Milano; Riccardo Righini; Concetta Elisa Onesti; Maria Bassanelli; Rosa Falcone; Ida Paris; Salvatore Lauro; Paolo Marchetti


Clinical Colorectal Cancer | 2016

Association Between Proton Pump Inhibitors and Metronomic Capecitabine as Salvage Treatment for Patients With Advanced Gastrointestinal Tumors: A Randomized Phase II Trial

Paolo Marchetti; Annalisa Milano; Chiara D'Antonio; Adriana Romiti; Rosa Falcone; Michela Roberto; Stefano Fais


Current Signal Transduction Therapy | 2012

Tailored angiogenesis inhibition in cancer therapy: Respecting the heart to improve the net outcome

Jasmine Passerini; Adriana Romiti; Chiara D'Antonio; Vittoria Mastromarino; Paolo Marchetti; Massimo Volpe; Elena Conti


Annals of Oncology | 2016

P-0395-Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic Capecitabine

Michela Roberto; Adriana Romiti; Luana Lionetto; Chiara D'Antonio; Concetta Elisa Onesti; Andrea Botticelli; Annalisa Milano; Rosa Falcone; Mario Occhipinti; Federica Mazzuca; Maurizio Simmaco; Paolo Marchetti


Archive | 2014

Metronomic capecitabine in metastatic colorectal cancer: a phase II trial

Michela Roberto; Chiara D'Antonio; Adriana Romiti; Annalisa Milano; Rosa Falcone; Valeria Durante; Federica Mazzuca; Concetta Elisa Onesti; Viola Barucca; Riccardo Righini; Paolo Marchetti

Collaboration


Dive into the Chiara D'Antonio's collaboration.

Top Co-Authors

Avatar

Paolo Marchetti

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Adriana Romiti

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Annalisa Milano

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Michela Roberto

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Rosa Falcone

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Viola Barucca

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Riccardo Righini

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Valeria Durante

Sapienza University of Rome

View shared research outputs
Top Co-Authors

Avatar

Roberta Di Rocco

Sapienza University of Rome

View shared research outputs
Researchain Logo
Decentralizing Knowledge